Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Hepatology (Baltimore, Md.) - 1 Jul 2000

Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P, Murray A

Abstract excerpt

Lamivudine has been shown to be an effective therapy for chronic hepatitis B, but resistance to this nucleoside agent is common after prolonged use. Five patients with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 9 to 19 months of treatment. In 4 patients this occurred after liver transplantation and the remaining individual had stable cirrhosis. In each case, resistance was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Organophosphonates

Source

Identifiers

PMID: 10869300
DOI: 10.1053/jhep.2000.8626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.PMID 10869300Read ↗

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.Semantic proximity Read ↗

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.Semantic proximity Read ↗

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.Semantic proximity Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.Semantic proximity Read ↗

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure.Semantic proximity Read ↗

Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Semantic proximity Read ↗

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.